Introduction
Gastric cancer is the fourth most common cancer and the second leading cause of cancer-related death worldwide. In 2002, about 934 000 people were diagnosed with gastric cancer, and approximately 700 000 died of the disease [1] .
Lymph node (LN) status is an important prognostic factor regarding long-term survival [2, 3] ; in patients with N0 gastric cancer, the 5-year survival rate (after surgical treatment) is 86.1%, whereas in patients with N1, N2, and N3 gastric cancer, survival rates dramatically decrease to 58.1%, 23.3%, and 5.9% [3] . Patients with T1 tumors have a low risk of LN metastasis: 2.2% in T1a (mucosal) and 17.9% in T1b (submucosal) cancer [4] . In patients with T2 and those with T3 tumors, LN metastases rise to 44% and 64% [5] . The extent to which LN dissection should be performed is still a topic of debate [5] [6] [7] . Because extended lymphadenectomy is associated with high morbidity and mortality, patients without LN metastasis should be spared from undergoing such an aggressive procedure. Pretreatment knowledge of LN status would thus be extremely helpful for determining prognosis and planning the optimal extent of lymphadenectomy. In addition, pretreatment knowledge of LN status may help in selecting patients who might benefi t most from neoadjuvant chemotherapy [8] .
As imaging technology continues to evolve [9] , the purpose of this study was to systematically review the current role of imaging in assessing LN status in gastric cancer. This study reviews the role of imaging in discriminating node-negative from node-positive patients, rather than its role in assessing nodal stage according to the TNM or Japanese Gastric Cancer Association (JGCA) classifi cations.
Methods

Search strategy
A computer-aided search of the PubMed/MEDLINE and Embase databases was conducted to fi nd relevant publications on the diagnostic performance of abdominal ultrasonography (AUS), endoscopic ultrasonography (EUS), multidetector-row computed tomography (MDCT), magnetic resonance imaging (MRI), 18 Ffl uoro-2-deoxyglucose positron emission tomography (FDG-PET), and FDG-PET/CT fusion, in assessing LN status in gastric cancer. The following search terms were used: ("gastric cancer" or "stomach cancer" or "gastric carcinoma" or "stomach carcinoma") and ("node metastasis" or "node metastases" or "nodal metastasis" or "nodal metastases" or "node involvement" or "nodal involvement" or "metastatic nodes" or "metastatic lymph nodes" or "lymphatic metastasis" or "lymphatic metastases" or "lymphatic involvement" or "lymph node involvement" or "lymph node metastatic disease" or "lymph node status" or "lymph node staging" or "N staging" or "TNM") and ("ultrasound" or "sonography" or "ultrasonography" or "endoscopic ultrasound" or "endoscopic ultrasonography" or "EUS" or "computed tomography" or "CT" or "CAT" or "magnetic resonance" or "MR imaging" or "MRI" or "magnetic resonance tomography" or "nuclear magnetic resonance" or "NMR" or "fl uorodeoxyglucose" or "2-fl uoro-2-deoxy-D-glucose" or "FDG" or "positron emission tomography" or "positron-emission tomography" or "PET"). No beginning date limit was used. The search was updated until July 7, 2008 . To expand our search, bibliographies of articles which fi nally remained after the selection process were screened for potentially suitable references.
Study selection
Studies investigating the diagnostic performance of AUS, EUS, MDCT (defi ned as CT with four or more detectors), MRI, FDG-PET, and/or FDG-PET/ CT fusion in assessing LN status in patients with newly diagnosed, histologically proven gastric cancer were eligible for inclusion. Only studies dealing with adenocarcinoma were included, because this is overwhelmingly the most important and most common malignant tumor that occurs in the stomach (range, 90% to 95%) [10] . Review articles, metaanalyses, abstracts, editorials or letters, case reports, studies involving ten or fewer patients with gastric cancer, tutorials, guidelines for management, and non-English-language articles were excluded. Studies performed in animals and ex vivo studies were also excluded. Studies in which patients were presurgically treated with radiotherapy or chemotherapy, which may cause downstaging, were excluded. Studies which investigated only patients with gastric cancer confi ned to a certain part of the stomach (e.g., the gastroesophageal junction) were excluded. Studies which provided insuffi cient data to construct a 2 × 2 contingency table to calculate sensitivity and specifi city for detecting LN metastasis on a per-patient basis were excluded. When data were presented in more than one article, the article with the largest number of patients was chosen.
Two researchers (R.M.K., T.C.K.) independently reviewed the titles and abstracts of the retrieved articles, applying the inclusion and exclusion criteria mentioned above. Articles were rejected if they were clearly ineligible. The same two researchers then independently reviewed the full-text version of the remaining articles to determine their eligibility for inclusion. Disagreements were resolved in a consensus meeting.
Data analysis
For each included study, information was collected concerning year of publication, country of origin, number of patients, technical details of the imaging modality under investigation, criteria for positivity, interpreter(s), and applied reference standard.
The methodological quality of the included studies was assessed in terms of the potential for bias (internal validity) and lack of generalizability (external validity). For this purpose, a checklist adapted from Kelly et al. [11] and Whiting et al. [12, 13] was used. The complete criteria list is presented in Table 1 . Internal validity criteria and external validity scores were scored as positive (adequate methods) or negative (inadequate methods, potential bias). If insuffi cient information was provided on a specifi c item, a negative score was given. Two reviewers (R. M. K., T. C. K.) independently assigned the scores. Disagreements between the two researchers were discussed and resolved by consensus. Subtotals were calculated for internal (maximum eight) and external (maximum fi ve) validity separately. Total quality scores were expressed as a percentage of the maximum score. Studies which had a percentage of the maximum score of 60 or greater were considered to be of high methodological quality. Studies which had a percentage of the maximum score of less than 60 were considered to be of low methodological quality.
Sensitivities and specifi cities for the detection of LN metastasis (with corresponding 95% confi dence intervals [CIs]) were calculated from the original numbers given in the included studies, for each imaging modality.
Forest plots for sensitivities and specifi cities were constructed. The means of sensitivities and specifi cities between studies of high and low methodological quality were compared by using a paired samples t-test. The level of statistical signifi cance was set at 0.05. Statistical analyses were executed using Statistical Package for the Social Sciences version 12.0 software (SPSS, Chicago, IL, USA).
Results
Literature search
The computer-aided search revealed 1035 articles from PubMed/MEDLINE and 889 articles from Embase. Reviewing titles and abstracts from PubMed/MEDLINE revealed 87 studies potentially eligible for inclusion. Reviewing titles and abstracts from Embase revealed 66 articles potentially eligible for inclusion, of which 62 were already identifi ed by the PubMed/MEDLINE search. Thus, 91 articles remained for possible inclusion and were retrieved in full-text version. Screening references of these articles did not result in other potentially relevant articles. After reviewing the full article, 37 articles were excluded, the majority (n = 21) because they provided insuffi cient data to construct a 2 × 2 contingency table to calculate sensitivity and specifi city for the detection of LN metastasis. Other reasons for exclusion were: same data were used in a later study (n = 7), patients examined with a single-slice CT scanner instead of with an MDCT scanner (n = 2), diagnostic performance for detecting LN metastasis was not investigated (n = 4), patients with esophageal and gastric cancer mixed (n = 1), patients with lymphomas and gastric cancer mixed (n = 1), and fewer than 10 patients with gastric cancer included (n = 1). Eventually, 6 AUS studies, 30 EUS studies, 10 MDCT studies, 3 (conventional) MRI studies, 4 FDG-PET studies, and 1 FDG-PET/CT fusion study were included in this systematic review. The characteristics of the included studies are presented in Tables 2 to 7 
Methodological quality assessment
For each of the included studies, 13 methodological quality items were assessed (Table 8 ).
• For the AUS studies, the total score for combined internal and external validity, expressed as a fraction of the maximum score, ranged from 31% to 69% (median, 58%). Three AUS studies [23, 42, 53] were of high methodological quality (percentage of the maximum score of 60 or greater).
• For the EUS studies, the total methodological quality score ranged from 38% to 77% (median, 54%). Ten EUS studies [19, 29, 34, 37, 41, 43, 44, 48, 50, 61] were of high methodological quality.
• For the MDCT studies, the total methodological quality score ranged from 38% to 85% (median, 70%). Eight MDCT studies [14, 18, 21, 22, 31, 32, 35, 39] were of high methodological quality.
• For the MRI studies, the total methodological quality score ranged from 46% to 77% (median, 62%). Two MRI studies [45, 47] were of high methodological quality.
• For the FDG-PET studies, the total methodological quality score ranged from 46% to 62% (median, 58%). Two FDG-PET studies [28, 30] were of high methodological quality.
• For the FDG-PET/CT fusion study, the total methodological quality score was 54%.
Staging performance
The sensitivities and specifi cities of the included studies are displayed in Table 9 and Fig. 1 .
• The sensitivity and specifi city of AUS for the detection of LN metastasis varied between 12.2% and 80.0% (median, 39.9%) and 56.3% and 100% (median, 81.8%). There was no signifi cant difference between the mean sensitivity of AUS studies with high and low methodological quality (53.2% vs 36.6%; P = 0.697). There also was no signifi cant difference between the mean specifi city of studies with high and low methodological quality (73.3% vs 86.4%; P = 0.166).
• The sensitivity and specifi city of EUS varied between 16.7% and 96.8% (median, 70.8%) and 48.4% and 100% (median, 84.6%). There was no signifi cant difference between the mean sensitivity of EUS studies with high and low methodological quality (69.1% vs 64.1%; P = 0.551). There also was no signifi cant difference between the mean specifi city of studies with high and low methodological quality (81.8% vs 82.8%; P = 0.827).
• The sensitivity and specifi city of MDCT varied between 62.5% and 91.9% (median, 80.0%) and 50.0% and 87.9% (median, 77.8%). There was no signifi cant difference between the mean sensitivity of MDCT studies with high and low methodological quality (80.1% vs 75.0%; P = 0.331). There also was no signifi cant difference between the mean specifi city of studies with high and low methodological quality (82.0% vs 75.5%; P = 0.473).
• The sensitivity and specifi city of MRI varied between 54.6% and 85.3% (median, 68.8%) and 50.0% and 100% (median, 75.0%). The mean sensitivity and specifi city of the MRI studies with high [23] 2006 − + − + + + − + + + − + − 5 3 62 Liao et al. [33] 2004 − − − − − + − + + + − − − 2 2 31 Lee et al. [42] 2001 − − − + + + − + + + + + + 4 5 69 Düx et al. [53] 1997 + − + + − + − + + − + + + 5 4 69 Kim et al. [54] 1997 − − + − + + − − + + − + + 3 4 54 Stell et al. [57] 1996 − − − − + − − + + + + + + 2 5 54 EUS Lok et al. [17] 2008 − − − − + − − − + + + − + 1 4 38 Bentrem et al. [19] 2007 + − − + + + − + + − + + + 5 4 69 Tan et al. [20] 2007 − − + + + + − + + + − − − 5 2 54 Arocena et al. [24] 2006 + − − − + + − − + + − + + 3 4 54 Ganpathi et al. [25] 2006 − − − − + + − + + + + − + 3 4 54 Tsendsuren et al. [26] 2006 − − − + + + − + + + − − − 4 2 46 Ang et al. [27] 2006 + − − − + + − − + − − + − 3 2 38 Potrc et al. [29] 2006 + + − + + + − + + − − + + 6 3 69 Polkowski et al. [34] 2004 + − − − + + − + + + + + + 4 5 69 Bhandari et al. [35] 2004 + − − − + + − + + + − − + 4 3 54 Javaid et al. [36] 2004 − − − + + + − + + + − + − 4 3 54 Habermann et al. [37] 2004 + − − + + + − + + + + − + 5 4 69 Xi et al. [40] 2003 − − − + + + − + + + − + − 4 3 54 Chen et al. [41] 2002 − − + + + + − + + + + + + 5 5 77 Willis et al. [43] 2000 + − − + + + − + + + + + − 5 4 69 Tseng et al. [44] 2000 − − − + + + − + + + − + + 4 4 62 Mancino et al. [46] 2000 − − − + + + − + + + − − − 4 2 46 Akahoshi et al. [48] 1998 + − − − + + − + + + + + − 4 4 62 Hunerbein et al. [49] 1998 + − − − + + − + + − − − + 4 2 46 Wang et al. [50] 1998 + − − + + + − + + + − + − 5 3 62 Hamada et al. [52] 1997 − − − + + + − + + + − − − 4 2 46 Hunerbein et al. [55] 1996 + − − − − + − + + − + + − 3 3 46 François et al. [56] 1996 + − − − + + − + + + − + − 4 3 54 Perng et al. [58] 1996 + − − + + − − − + + − + − 3 3 46 Smith et al. [60] 1993 − − − + + + − + + − − − + 4 2 46 Ziegler et al. [61] 1993 + − − + + + − − + + + + − 4 4 62 Grimm et al. [62] 1993 + − − − − + − + + + − − − 3 2 38 Dittler and Siewert [63] 1993 − − − + + + − + + + + − − 4 3 54 Botet et al. [64] 1991 − − − + + + − − + + + − − 3 3 46 Tio et al. [65] 1990 − − − + + + − + + + − − − 4 2 46 MDCT Kim et al. [14] 2008 − − − − + + − + + + + + + 3 5 62 Chamadol et al. [15] 2008 − − − − + + − + + + − + + 3 4 54 Yang et al. [16] 2008 − − − + + − − − + + − + − 2 3 38 Chen et al. [18] 2007 + − − + + + − + + + + + + 5 5 77 Chen et al. [21] 2007 + − + − + + − + + + + + + 5 5 77 Yang et al. [22] 2007 + − − + + − − + + + − + + 4 4 62 Kim et al. [31] 2005 + − − + + + − + + + + + + 5 5 77 Shinohara et al. [32] 2005 + − + + + + − + + + + + + 6 5 85 Bhandari et al. [35] 2004 + − − − + + − + + + − + + 4 4 62 Stabile Ianora et al. [39] 2003 + − + + + + − + + + − + + 6 4 77 MRI Arocena et al. [24] 2006 + − − − − + − − + + − + + 2 4 46 Kim et al. [45] 2000 + − + − + + − + + + + + + 5 5 77 Kang et al. [47] 2000 − − + + + + − − + + − + + 4 4 62 FDG-PET Mukai et al. [28] 2006 − − − + + + − − + + + + + 3 5 62 Yun et al. [30] 2005 − + − + + + − + + + − − + 5 3 62 Tian et al. [38] 2004 + − − + + − − + + − − + − 4 2 46 Yeung et al. [51] 1998 − − − + + − − + + + − + + 3 4 54 FDG-PET/CT Yang et al. [16] 2008 − − − + + + − + + + − + − 4 3 54 Table 9 . Abdominal ultrasonography (AUS), endoscopic ultrasonography (EUS), multidetector-row computed tomography (MDCT), magnetic resonance imaging (MRI), 18 F-fl uoro-2-deoxyglucose positron emission tomography (FDG-PET), and 18 Ffl uoro-2-deoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) fusion studies: sensitivity and specifi city for detection of nodal metastasis 18 F-fl uoro-2-deoxyglucose positron emission tomography (FDG-PET), and FDG-PET/CT fusion; forest plots of sensitivity and specifi city for depiction of nodal metastasis. 1, Axial slices; 2, multiplanar reformation methodological quality were 77.1% and 87.5%. There was one MRI study [24] with low methodological quality, with sensitivity of 54.6% and specifi city of 50.0% • The sensitivity and specifi city of FDG-PET varied between 33.3% and 64.6% (median, 34.3%) and 85.7% and 97.0% (median, 93.2%). There was no signifi cant difference between the mean sensitivity of FDG-PET studies with high and low methodological quality (34.3% vs 49.0%; P = 0.515). There also was no signifi cant difference between the mean specifi city of studies with high and low methodological quality (96.7% vs 87.9%; P = 0.131).
• The sensitivity and specifi city of the FDG-PET/CT fusion study were 54.7% and 92.2%, respectively.
Discussion
This systematic review demonstrates that, to date, no imaging modality consistently achieves both high sensitivity and high specifi city in the detection of LN metastasis in gastric cancer. The sensitivities and specifi cities of AUS, EUS, and MRI varied from poor (<60%) to high (≥80%). The sensitivity of MDCT varied from moderate (60%-80%) to high, whereas the specifi city varied from poor to high. The sensitivity of FDG-PET varied from poor to moderate, whereas the specifi city was high. Similarly, The sensitivity of FDG-PET/CT fusion was poor, whereas the specifi city was high. For all imaging modalities, there were no signifi cant differences between the mean sensitivities and specifi cities of the high-quality and low-quality studies. There were too many missing or mixed values for a substantial number of study characteristics and insuffi cient studies to use meta-regression or to perform subgroup analysis to examine other possible causes for the heterogeneous results. Possible causes are variations in patient characteristics and scanning protocols, and the use of different diagnostic criteria and implicit thresholds. Yet another likely cause of the heterogeneous results is the moderate methodological quality of the included studies. Only one AUS study had a prospective study design [53] , in only one EUS study the time interval between EUS and the reference test was less than 16 days [29] , and in none of the FDG-PET(/CT fusion) studies the time interval between FDG-PET(/CT fusion) and the reference test was less than 16 days. Except for one AUS study [23] , one EUS study [29] , and one FDG-PET study [30] , none of the included studies applied histopathological analysis after ≥D2 lymphadenectomy in all patients. Furthermore, the quality of pathological examinations of excised LNs, the skills of the surgeons, and the tumor extensions may also have affected sensitivity and specifi city. Finally, test review bias may have been present in all the included studies. Because of the heterogeneity and moderate methodological quality of the included studies, we omitted calculation of pooled sensitivities and specifi cities. AUS and EUS rely on the morphological characteristics, echogenicity, and size of LNs as criteria to defi ne metastasis. The latter may explain the insuffi cient diagnostic performance of AUS and EUS, because metastases in normal-sized LNs may be missed. A study investigating the correlation between LN size and metastatic infi ltration in patients with gastric cancer found that 80% of tumor-free LNs had a diameter of 5 mm or less [66] . However, 55% of the metastatic lymph nodes were also 5 mm or less in diameter [66] . Thus, LN size only is not a reliable indicator of LN metastasis in gastric cancer. Furthermore, AUS is limited in obese patients or when overlying bowel gas is present, because in these circumstances adequate visualization of LNs is hampered. At high transducer frequencies, EUS has a limited depth of penetration, making visualization of more distant LNs diffi cult. Another major disadvantage of both AUS and EUS is their inherent operator-dependency. The diagnostic performance of AUS and EUS in detecting LN metastasis in gastric cancer has been studied since the early 1990s, and, as can be seen in Table 9 and Fig. 1 , the diagnostic accuracy of AUS and EUS has not signifi cantly improved over time.
The included MDCT studies mainly used LN size, but also degree of enhancement and LN shape as criteria to defi ne malignancy. Although MDCT is much less subject to observer variability compared to AUS and EUS, metastases in LNs of normal size can still be missed. Remarkably, one MDCT study [39] defi ned all identifiable LNs as metastatic. Surprisingly, this study still reported a sensitivity of 89.5% and a specifi city of 75.0%. The included MDCT studies used 4-to 64-section MDCT scanners. It is unlikely that newer MDCT technology, such as the application of 128-to 256-section MDCT scanners or dual-source technology, will improve diagnostic performance, because current MDCT scanners already have the ability to detect LNs of 5 mm or less in diameter.
The included conventional MRI studies all used different pulse sequences to obtain images. Two studies also obtained post-contrast images. All the studies used LN size as the criterion to defi ne malignancy, and one study also defi ned enhancing LNs as metastatic. An explanation for the insuffi cient diagnostic performance of conventional MRI is its inability to identify metastatic LNs of normal size. Functional MRI techniques (including ultrasmall particles of iron oxide [USPIO]-enhanced MR lymphography and diffusion-weighted MRI) or a combination of conventional and functional MRI may be more accurate than conventional MRI alone. USPIO-enhanced lymphography allows the identifi cation of malignant nodal infi ltration independent of LN size. After intravenous administration, USPIOs are taken up by macrophages in the reticuloendothelial system, predominantly within the LNs. Normal homogeneous uptake of USPIOs in nonmetastatic LNs shortens the T2 and T2*, turning these nodes hypointense on T2-and T2*-weighted images, whereas malignant LNs lack uptake and remain hyperintense. USPIO-enhanced lymphography indeed has been shown to achieve higher diagnostic precision than does conventional, unenhanced MRI for the detection of LN metastases of various tumors [67] . Although no USPIO-enhanced lymphography studies were identifi ed for inclusion in this systematic review, its usefulness in detecting metastatic LNs in gastric cancer has already been demonstrated by a recent pilot study in 17 patients [68] . MR lymphography using other contrast agents may also have high potential [69] , but this remains to be investigated. Diffusion-weighted MRI is another functional imaging technique, based on water diffusivity. Cancerous lesions which have architectural malformations are highlighted by this technique, because they have a restricted diffusion [70] . However, no studies on diffusion-weighted MRI were identifi ed for inclusion in this systematic review.
A possible reason for the reported low to moderate sensitivity of FDG-PET is its limited resolution; current FDG-PET units have a 4-to 5-mm resolution [71] , but it has been reported that 14.5% of metastatic LNs in gastric cancer have a largest diameter of less than 3 mm [66] . Consequently, these LN metastases can be missed by FDG-PET. Low FDG uptake of metastatic LNs may also explain the low sensitivity of FDG-PET; Stahl et al. [72] found that diffusely growing and mucuscontaining gastric cancers may exhibit low FDG uptake. Another possible explanation for the low sensitivity of FDG-PET is the masking of perigastric LNs by FDG uptake of the adjacent primary tumor. On the other hand, FDG uptake of the primary tumor may mimic involvement of adjacent LNs, thereby decreasing specifi city. Similarly, physiological FDG uptake of the stomach [73] may also mask or mimic metastatic perigastric LNs. FDG-PET/CT fusion provides both anatomic and functional information, and allows more accurate localization of foci with increased FDG uptake than stand-alone PET; this may reduce the problems of missing metastatic LNs with low FDG uptake, physiological FDG uptake being misinterpreted as pathological, and false localization of disease [74] . Additional advantages of using a combined PET/CT scanner are decreased scanning time and improved quality of the FDG-PET images [74] . However, the results of the FDG-PET/CT fusion study [16] included in this systematic review suggest that FDG-PET/CT fusion does not improve sensitivity (or specifi city). Of note, however, the poor sensitivity may mainly be a result of the limited resolution of the PET/CT scanner used in that study [16] , which is only 6.3 mm [75] . The performance of PET/CT scanners with a higher resolution still has to be determined, to our knowledge.
Laparoscopic sentinel node (SN) biopsy is another promising tool to more accurately determine nodal status in patients with gastric cancer. The SN concept is based on the premise that tumor cells will preferentially metastasize to the fi rst draining LN in the regional lymphatics, the SN. After identifying the SN (by use of a radionucleotide tracer and/or dye), and laparoscopic biopsy, LN metastasis is confi rmed or ruled out by histological examination. A disadvantage of laparoscopic SN biopsy, however, is its invasiveness. Although studies on laparoscopic SN biopsy have shown its potential [76] [77] [78] [79] , various technical and material limitations still have to be overcome. Also, the reliability of laparoscopic SN biopsy has yet to be determined by multicenter prospective clinical trials [80] .
In conclusion, AUS, EUS, MDCT, conventional MRI, and FDG-PET do not achieve consistently high sensitivity and specifi city in detecting LN metastasis in patients with gastric cancer. The value of highresolution PET/CT fusion and functional MRI techniques still has to be determined.
